Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab in active ankylosing spondylitis (phase 3, China)
CTR20192059Phase 3Completed
- Sponsor
- UCB
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of bimekizumab in ankylosing spondylitis (AS), sponsored by UCB. Started Oct 2019; status: completed.
02
Drugs
bimekizumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on CTR20192059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192059.